Literature DB >> 10684989

Immunogenicity of an E. coli extract after oral or intraperitoneal administration: induction of antibodies against pathogenic bacterial strains.

M Huber1, W Baier, A Serr, W G Bessler.   

Abstract

For the treatment of recurrent infections of the urinary tract, a bacterial extract (OM-89) consisting of immunostimulating components derived from 18 Escherichia coli strains is orally applied to patients. We investigated in a mouse model the immunogenicity of the bacterial extract after intraperitoneal or oral administration. After repeated administration of the extract, serum IgG and IgA responses against the E. coli strains used for the preparation of OM-89 were obtained. This antisera also recognized a number of bacterial strains isolated from patients with urinary tract and enterohemorrhagic E. coli infections, and bound to a variety of other pathogenic strains. Moreover, the supernatants of cell cultures prepared from the urogenital tract of mice immunized with OM-89 contained increased levels of strain specific and of total IgG and IgA. Our findings may contribute to explain the therapeutic effect of OM-89 demonstrated in clinical studies.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10684989     DOI: 10.1016/s0192-0561(99)00064-8

Source DB:  PubMed          Journal:  Int J Immunopharmacol        ISSN: 0192-0561


  5 in total

1.  Vaccine Development for the Prevention of Urinary Tract Infections.

Authors:  Walter J. Hopkins; David T. Uehling
Journal:  Curr Infect Dis Rep       Date:  2002-12       Impact factor: 3.725

2.  Anti-inflammatory effect of an Escherichia coli extract in a mouse model of lipopolysaccharide-induced cystitis.

Authors:  Seung-Ju Lee; Sae Woong Kim; Yong-Hyun Cho; Moon Soo Yoon
Journal:  World J Urol       Date:  2005-12-31       Impact factor: 4.226

3.  Effects of probiotics on Zebrafish model infected with Aeromonas hydrophila: spatial distribution, antimicrobial, and histopathological investigation.

Authors:  Sheida Ehsannia; Hamed Ahari; Shapour Kakoolaki; Seyed Amirali Anvar; Shima Yousefi
Journal:  BMC Microbiol       Date:  2022-06-27       Impact factor: 4.465

Review 4.  Drug and Vaccine Development for the Treatment and Prevention of Urinary Tract Infections.

Authors:  Valerie P O'Brien; Thomas J Hannan; Hailyn V Nielsen; Scott J Hultgren
Journal:  Microbiol Spectr       Date:  2016-02

Review 5.  Waging war against uropathogenic Escherichia coli: winning back the urinary tract.

Authors:  Kelsey E Sivick; Harry L T Mobley
Journal:  Infect Immun       Date:  2009-11-16       Impact factor: 3.441

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.